ReviewIndian dermatology online journal
Newer Topical Treatments in Skin and Nail Dermatophyte Infections.
Review in Indian dermatology online journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Economic Burden and Cost Differences Between Branded and Generic Topical Antifungals in India.Cureus · 2026Article
- Rising antifungal resistance inFrontiers in microbiology · 2026Review
- Phospholipid-Based Ultraflexible Nanovesicular Gel of Sertaconazole Nitrate for the Treatment of Skin Fungal Infections: Statistical Optimization, In Vitro and Preclinical Assessment.Gels (Basel, Switzerland) · 2025Article
- Treatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte,Journal of clinical microbiology · 2025Review
- Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced byPharmaceutics · 2024Article
- Antifungal Activity ofAntibiotics (Basel, Switzerland) · 2024Article
- Secondary metabolites in topical infectious diseases and nanomedicine applications.Nanomedicine (London, England) · 2024Review
- Evaluation of the efficacy of novel topical antifungal agents against dermatophytes in North India: A prospective study.Current medical mycology · 2024Article
- Graphene Scaffolds: A Striking Approach to Combat Dermatophytosis.Nanomaterials (Basel, Switzerland) · 2023Article
- Advances of liposomal mediated nanocarriers for the treatment of dermatophyte infections.Heliyon · 2023Review
- Species Distribution and Antifungal Susceptibility Profile of Dermatophytes from a Tertiary Care Centre in North India.Journal of laboratory physicians · 2022Article
- Allylamines, Benzylamines, and Fungal Cell Permeability: A Review of Mechanistic Effects and Usefulness against Fungal Pathogens.Membranes · 2022Review
- The Human Mycobiome: Colonization, Composition and the Role in Health and Disease.Journal of fungi (Basel, Switzerland) · 2022Review
- Protective manifestation of herbonanoceuticals as antifungals: A possible drug candidate for dermatophytic infection.Health science reports · 2022Article
- Emerging Trends in the Use of Topical Antifungal-Corticosteroid Combinations.Journal of fungi (Basel, Switzerland) · 2022Review
- Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.Mycoses · 2022Article
- A Review on Antifungal Efficiency of Plant Extracts Entrenched Polysaccharide-Based Nanohydrogels.Nutrients · 2021Review
- Epidemiology of Dermatophytes in Belgium: A 5 Years' Survey.Mycopathologia · 2021Article
- Sophorolipid Biosurfactant Can Control Cutaneous Dermatophytosis Caused byFrontiers in microbiology · 2020Article
- MultiresistantInfection and drug resistance · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatophytes are amongst the most common causative agents of fungal infections worldwide and widespread in the developing countries. Various studies have found the significantly rising trend of this infection in India especially in last 4-5 years. The growing epidemic of recurrent/chronic dermatophytosis has led to the need for newer antifungal agents and/or preparations. Furthermore, resistance to commonly used topical and oral antifungals has increased alarmingly. Significantly increasing resistance has led to state of anxiety in physicians and significant distress to the patients socially, emotionally, and financially. Newer formulations or newer derivatives of existing drug classes and few newer drug classes are being developed to tackle this menace. Other forms of local therapies including lasers and photodynamic therapy are still in developmental phase and still need to be optimized in terms of dosing schedule, frequency of use and duration of therapy. Moreover, cost of these therapies remained most important obstacle in developing countries like India. We are hereby reviewing the newer formulations of topical therapies and drugs/interventions in experimental phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.